The ASA has prohibited a billboard advert for a £49 face serum after determining that claims it could make users look up to five years younger were misleading and unsubstantiated. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which appeared at Balham tube station in London, stated the product was “clinically proven” founded on a study of 160 people. However, the watchdog found significant flaws in the study design, such as the lack of a control group and dependence on subjective self-reporting from participants. The grievance was lodged in November 2025, prompting the ASA investigation that ultimately deemed the advertisement misleading and banned it from appearing in its current form.
The Banned Campaign and Its Controversial Claims
The Eucerin marketing campaign relied heavily on a four-week trial involving 160 individuals who were merely requested to self-report how much younger they felt they looked after using the serum. This methodology prompted immediate concerns for the ASA, which identified several critical weaknesses in the study design. Most notably, the study did not include a comparison group—a essential component in scientific studies that would have allowed researchers to assess outcomes against a reference point. The lack of such controls meant there was no way to establish whether any apparent benefits were genuinely attributable to the serum or merely the consequence of placebo response, inherent skin differences, or additional outside influences.
Beiersdorf, the organisation behind Eucerin, attempted to substantiate the “up to five years younger” claim by arguing it represented a real upper result rather than a standard result. However, the concerns raised by the ASA extended beyond the main investigation. The watchdog noted that the serum had been evaluated in a different environment to the United Kingdom, creating doubt about whether findings would apply to consumers in Britain. Additionally, three additional pieces of evidence submitted by Beiersdorf consisted completely of unpublished studies, whilst a fourth item—a study that had been peer-reviewed on the active ingredient—did not even evaluate the serum itself, additionally weakening the evidence supporting the bold anti-ageing claims.
- Study lacked comparative baseline to confirm actual product efficacy
- Self-reporting by participants created personal bias into outcomes
- Testing carried out in alternative climate conditions than UK market
- Backing evidence mostly unpublished and questionable in methodology
Compliance Issues and Problematic Approach
Why the Research Did Not Meet Benchmarks
The ASA’s examination uncovered fundamental flaws in how Beiersdorf executed and communicated its research. The lack of clear recruitment information resulted in the watchdog could not verify whether participants were genuinely representative of the wider consumer population or if sampling bias had distorted findings towards desirable conclusions. Without knowing how volunteers were recruited, whether they had prior experience with skincare products, or if they possessed prior loyalty for the brand, the trustworthiness of their feedback became deeply problematic. These procedural shortcomings are precisely the kind that regulatory bodies examine closely when evaluating claims that could influence purchasing decisions.
Self-reporting by study participants added a significant layer of subjective bias into the findings. Asking individuals to estimate how many years younger they appeared is fundamentally problematic, as perceptions of ageing are highly individual and influenced by psychological factors, lighting conditions, and individual expectations. The ASA rightly questioned whether participants’ responses reflected genuine physical changes or merely their hopes and beliefs about the product’s efficacy. This distinction holds significant weight when a company seeks to market a £49 serum as “clinically proven”—a phrase suggesting rigorous, objective scientific validation rather than individual subjective views.
- No comparison cohort meant impossible to isolate product’s true effects
- Selection methodology undisclosed, introducing selection bias concerns
- Subjective self-assessment cannot constitute scientific evidence of efficacy
- Varying environmental conditions undermined applicability to UK consumers
- Supporting evidence mostly undisclosed, restricting independent scientific scrutiny
Common Challenge with Beauty Advertising
The Eucerin serum ban is simply the most recent example of false assertions that has affected the cosmetics advertising industry for years. Beauty companies have repeatedly pushed the boundaries of acceptable marketing language, utilising aspirational language and pseudo-scientific language to convince consumers that products provide transformative results. Lianne Sykes, an marketing specialist in aesthetics who consults with firms on responsible marketing conduct, stresses that this issue is widespread rather than being isolated. Companies often place emphasis on persuasive marketing stories over rigorous substantiation, relying on the presumption that consumers will not scrutinise claims too closely or that regulatory enforcement will be slow.
The cosmetics industry gains from inherent demand among consumers for visible improvements in appearance, creating fertile ground for exaggerated assertions. When companies use phrases like “clinically proven” without meeting the stringent standards that such language requires, they undermine the trust consumers place in scientific terminology. The ASA’s findings suggest that Beiersdorf’s approach—presenting unpublished research, conducting studies in unfavourable environments, and using subjective self-assessment—represents a concerning but not uncommon strategy. Without regular monitoring and increased openness from suppliers, consumers stay susceptible to marketing claims that emphasise profit over honesty.
What People Should Scrutinise
Rather than taking beauty product claims at face value, consumers should develop a more critical approach to assessing cosmetic advertising. Sykes suggests asking fundamental questions when making purchases, notably when companies present bold assertions about noticeable outcomes. Understanding the testing methods used, who participates in studies, and what measures are measured can demonstrate whether claims are grounded in solid evidence or marketing spin. Consumers must recognise that clear skin typically results from steady practices and individual biology rather than dependence on a single miracle product, regardless of its price point or branding.
- How is skin condition systematically assessed and tracked over time?
- Were trials conducted on diverse age groups and skin conditions?
- Is the findings made public and independently verifiable by scientists?
- Does the testing environment match real-world conditions where consumers live?
Beiersdorf’s Response and Future Implications
Beiersdorf, the German multinational corporation that owns the Eucerin brand, has maintained that its products are supported by legitimate scientific research conducted in accordance with industry standards. The company justified its choice to state the claim as “up to” five years younger, contending this phrasing accurately reflected the true maximum outcome observed rather than a standard result. However, the ASA’s thorough examination of the research approach—including the lack of a control group, lack of transparency about participant recruitment, and dependence on subjective self-assessment—suggests that sector guidelines by themselves might not be adequate to protect consumers from misleading assertions.
The ban indicates a wider movement in regulatory enforcement against cosmetics advertising, though uncertainty persists about whether individual instances translate into widespread reform. Beiersdorf confirmed that the billboard advertisement is no longer active in the UK, but the ruling highlights key concerns about how widely similar claims exist throughout other products and marketing channels. If enforcement continues at this pace, companies may face increasing demands to commit resources to truly comprehensive clinical evidence rather than relying on the vagueness surrounding unverified research. For consumers, this case highlights the necessity of demanding transparency and scrutinising even long-standing brands.